Genzyme Must Give NICE More Data To Avoid New European Problem For Aubagio
This article was originally published in The Pink Sheet Daily
Executive Summary
Britain’s NICE wants more data to address uncertainties about the clinical and cost-effectiveness of Genzyme’s oral MS drug Aubagio.
You may also be interested in...
Discount Price May Position Aubagio For Greater Than Expected Uptake In Multiple Sclerosis
Wall Street projects modest sales for Sanofi/Genzyme’s recently approved MS drug, but by pricing it well below Gilenya and somewhat below established, widely used injectable drugs, the companies may position Aubagio for first-line use and greater than anticipated adoption by payers.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.